- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Drug guidance
Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Cancer
Blood and Immune System
17 February 2025
Published on 13 Sep 2024
Last Updated on 17 Feb 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended axicabtagene ciloleucel for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for treating patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. The decision was based on the unacceptable pricing proposal by the company.